Breaking News, Trials & Filings

GSK Resubmits Solzira NDA

GlaxoSmithKline and development partner XenoPort have resubmitted the NDA to the FDA requesting approval of Solzira Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
 
The FDA requested that the data in one study be reformatted. GSK also included recent data from other clinical studies. The withdrawal was not related to the content of the filing.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters